Ivosidenib Shows Activity in IDH1-Mutant Myelodysplastic Neoplasms

Consortium: French Myelodysplasia Group (GFM) · Partner: Servier · Drug: Ivosidenib · Trial: IDIOME (Phase II) · Indication: IDH1-Mutant Myelodysplastic Neoplasms · Date: August 25, 2026 Summary The French Myelodysplasia Group reported Phase II IDIOME results for single-agent ivosidenib in 48 older adults with IDH1-mutant…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
Sobi Licenses Lacutamab in $580 Million Deal
Neomorph – $100M Molecular Glue Financing
Dyne Seeks $300 Million After BLA Acceptance